(Q35909843)

English

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).

scientific article published on 7 November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

0 references

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Toni K Choueiri

1

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sabina Signoretti

6

object named as

Sabina Signoretti

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Suchun Cheng

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Angela Q Qu

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Jaromir Pastorek

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Michael B Atkins

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

publication date

7 November 2012

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Urologic Oncology

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

31

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1788-1793

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Updates on novel therapies for metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

27 July 2018

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

27 July 2018

The role of carbonic anhydrase IX overexpression in kidney cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

27 July 2018

Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

27 July 2018

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

27 July 2018

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4522691

24 September 2018

Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.004

7 January 2021

Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.07.004

7 January 2021

Identifiers

10.1016/J.UROLONC.2012.07.004

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35909843&oldid=1790859738"